v3.25.2
Segment Information (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment Reporting [Abstract]            
Number of reportable segments | segment         1  
Segment Reporting Information [Line Items]            
Revenue from collaborative arrangement $ 0   $ 100,762   $ 65,343 $ 100,762
Less:            
Research and development expenses 14,521,407   23,090,989   30,612,309 44,001,307
General and administrative 8,563,112   10,206,686   17,588,082 20,781,337
Total operating expenses 23,084,519   33,297,675   48,200,391 64,782,644
Interest income 610,638   1,307,358   1,418,715 2,807,648
Interest expense 0   0   0 (177,833)
Change in fair value of common stock warrant liability (1,878,010)   0   1,834,862 0
Gain (loss) on investment in affiliated entity 776,373   (334,294)   1,471,504 (460,312)
Net unrealized gain (loss) on available-for-sale equity securities 759,289   (20,820)   899,523 480,057
Other (expense) income, net (703,183)   7,571   (703,665) (674,647)
Net loss (23,519,412) $ (19,694,697) (32,237,098) $ (30,469,871) (43,214,109) (62,706,969)
INO-3107            
Less:            
Research and development expenses 3,930,320   11,042,995   7,437,662 18,688,659
INO-3112 And Other Immuno-oncology            
Less:            
Research and development expenses 1,437,759   1,562,832   2,752,843 3,583,582
Other programs            
Less:            
Research and development expenses 153,488   203,562   260,913 827,228
Engineering and device-related            
Less:            
Research and development expenses 5,084,662   4,838,666   10,146,472 8,589,927
Stock-based compensation            
Less:            
Research and development expenses 321,688   590,102   875,082 1,650,589
Other unallocated expenses            
Less:            
Research and development expenses 3,593,490   4,852,832   9,139,337 10,661,322
Reportable Segments            
Segment Reporting Information [Line Items]            
Revenue from collaborative arrangement 0   100,762   65,343 100,762
Less:            
General and administrative 8,563,112   10,206,686   17,588,082 20,781,337
Total operating expenses 23,084,519   33,297,675   48,200,391 64,782,644
Interest income 610,638   1,307,358   1,418,715 2,807,648
Interest expense         0 (177,833)
Change in fair value of common stock warrant liability 1,878,010   0   (1,834,862) 0
Gain (loss) on investment in affiliated entity 776,373   (334,294)   1,471,504 (460,312)
Net unrealized gain (loss) on available-for-sale equity securities 759,289   (20,820)   899,523 480,057
Other (expense) income, net (703,183)   7,571   (703,665) (674,647)
Net loss $ (23,519,412)   $ (32,237,098)   $ (43,214,109) $ (62,706,969)